- Overview of RET in Oncogenesis and the Role of RET Inhibitors in Cancer Therapy
- The Latest Evidence on RET Inhibition Strategies in RET Fusion–Positive NSCLC, RET-Mutant MTC, and RET Fusion–Positive Thyroid Cancer
- Tumor Board–Style Case Discussions by Multidisciplinary Faculty Panel
- Evidence-Based Testing Strategies to Detect RET Fusions and Mutations
- Audience Question and Answer Session
Date / Time
Marcia Brose, MD, PhD
Department of Otorhinolaryngology: Head & Neck Surgery
Department of Medicine, Division of Hematology/Oncology
Director, Center for Rare Cancers and Personalized Therapy
Director, Thyroid Cancer Therapeutics Program
Abramson Cancer Center
Karen Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Los Angeles, California
Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
The Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with RET-dependent NSCLC and thyroid cancer.
This program is intended for oncologists, oncology pathologists, and other healthcare providers who care for patients with thyroid and lung cancers.
Upon completion of this activity, participants should be able to:
- Evaluate the clinical utility of RET as a predictive biomarker for targeted therapy in NSCLC and thyroid cancer
- Apply current recommendations to identify patients who should receive testing, provide effective counseling, and tailor biomarker testing options to the individual patient’s needs
- Summarize ongoing research regarding the utility of selective RET inhibitors in patients with RET fusion–positive NSCLC, RET-mutant MTC, and RET fusion–positive thyroid cancer
- Compare and contrast the different methodologies and assays for identifying RET alterations
- Identify patients with RET-altered tumors who are candidates for ongoing clinical trials
- Develop a proactive management plan for adverse events associated with therapies used to treat RET fusion–positive NSCLC, RET-mutant MTC, and RET fusion–positive thyroid cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.